Canagliflozin (hemihydrate): SGLT2 Inhibitor for Diabetes Mellitus Research

Executive Summary:
- Canagliflozin (hemihydrate) is a small molecule SGLT2 inhibitor used extensively to study renal glucose reabsorption in metabolic disorder research (APExBIO C6434).
- It shows high selectivity for the sodium-glucose co-transporter 2 (SGLT2) and does not inhibit the mTOR pathway, according to recent drug-sensitized yeast screens (Breen et al., 2025).
- The compound is supplied at ≥98% purity, is insoluble in water, but dissolves readily in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) (APExBIO).
- Best practice parameters include storage at -20°C and immediate use of solutions to preserve activity (APExBIO).
- Its specificity and robust solubility profile make it a benchmark tool for diabetes mellitus and glucose homeostasis pathway research (Octocrylenechem).

Biological Rationale

Canagliflozin (hemihydrate) targets SGLT2, a membrane protein responsible for reabsorption of filtered glucose in the proximal renal tubule. SGLT2 inhibition reduces renal glucose reabsorption, increasing urinary glucose excretion and lowering systemic blood glucose. This mechanism directly addresses hyperglycemia, a hallmark of diabetes mellitus. SGLT2 inhibitors are validated as effective interventions for glucose homeostasis in both preclinical and clinical models (APExBIO). The compound's selectivity for SGLT2, without off-target mTOR pathway effects, further refines experimental interpretation (Breen et al., 2025). This article extends prior mechanistic discussions by contrasting SGLT2 specificity with mTOR pathway inhibitors, as previously outlined in Octocrylenechem (2023).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) is classified as a small molecule SGLT2 inhibitor. The compound binds to the sodium-glucose co-transporter 2 protein in the renal proximal tubule, competitively blocking glucose reabsorption. This inhibition leads to increased renal glucose excretion and a reduction in blood glucose concentrations. The chemical structure, (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (C24H26FO5.5S), confers high affinity and specificity for SGLT2. No significant inhibition is observed against mTOR or other kinases in validated yeast-based screens (Breen et al., 2025). This mechanistic distinction is further discussed in detail in Sitagliptinphosphate (2023), where SGLT2 selectivity is contrasted with broader kinase inhibition.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) exhibits ≥98% purity by HPLC and NMR in APExBIO lots, supporting reproducible research outcomes (APExBIO).
• Solubility benchmarks: insoluble in water, soluble in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) at room temperature (APExBIO).
• In the mTOR inhibitor yeast-screening platform, canagliflozin did not inhibit TOR1-dependent growth at concentrations up to 100 μM, evidencing no mTOR pathway inhibition (Breen et al., 2025).
• Canagliflozin demonstrates robust selectivity for renal glucose reabsorption inhibition, with no detectable off-target effects in validated kinase profiling studies (Octocrylenechem).
• Best storage conditions are at -20°C; solutions should not be stored long-term and are recommended for immediate use to ensure compound integrity (APExBIO).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is used in studies of glucose homeostasis, diabetes mellitus, metabolic syndrome, and renal physiology. It serves as a probe for SGLT2-dependent pathways in both in vitro and in vivo models. Its high purity and selectivity facilitate mechanistic studies and translational research. However, it is not suitable for mTOR pathway inhibition studies, as confirmed by recent yeast-based drug screens (Breen et al., 2025). This article updates and clarifies earlier reports such as Miglitol.com, providing new benchmarks for selectivity and workflow integration.

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) does not inhibit the mTOR/TOR pathway at concentrations up to 100 μM (Breen et al., 2025).
• It should not be used as a diagnostic or therapeutic agent; for research use only (APExBIO).
• Long-term storage of dissolved solutions is discouraged due to potential degradation (APExBIO).
• It is insoluble in water and must be dissolved in DMSO or ethanol for laboratory use.
• Not suitable for studies requiring broad-spectrum kinase inhibition.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) should be stored at -20°C and handled under dry conditions to avoid hydrolysis. Working solutions are best prepared fresh in DMSO or ethanol, with typical laboratory concentrations ranging from 10 μM to 100 μM depending on the assay. For in vitro work, ensure final DMSO content is compatible with cell viability. For in vivo studies, dosing regimens should be guided by published pharmacokinetic data and species-specific parameters. Quality control documentation from APExBIO confirms ≥98% purity for each lot (APExBIO), supporting reproducible experimental design. Researchers are encouraged to reference advanced workflow strategies and selectivity analyses detailed in Insulin-like-growth-factor-II-fragment-variant.com, which this article updates by incorporating the latest mTOR screening data.

Conclusion & Outlook

Canagliflozin (hemihydrate), as supplied by APExBIO, is a benchmark SGLT2 inhibitor for diabetes mellitus and metabolic disorder research. Its selectivity for renal glucose homeostasis pathways, confirmed lack of mTOR pathway inhibition, and robust purity profile support advanced experimental workflows. Future research may leverage this compound for combinatorial studies in metabolic syndrome and translational research, with confidence in its pathway specificity (Breen et al., 2025).